{
    "symbol": "IOVA",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 20:57:04",
    "content": " Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance\u00e2\u0080\u0099s goals, business focus, business plans, pre-commercial activities, clinical trials and results, regulatory interaction, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interaction, licenses and collaboration, cash position and expense guidance and future updates. Net loss for the nine-months ended September 30, 2022 was $290.6 million or $1.85 per share compared to a net loss of $242.9 million or $1.60 per share for the first nine-months of 2021. Research and development expenses were $72.5 million for the first quarter ended September 30, 2022, an increase of $7.1 million dollars compared to $65.4 million for the same period ended September 30, 2021. Research and development expenses were $214.2 million for the nine-months ended September 30, 2022, an increase of $30.8 million compared to $183.4 million for the same period ended September 30, 2021. General and administrative expenses were $27.9 million for the third quarter ended September 30, 2022, an increase of $7 million compared to $20.9 million for the same period ended September 30, 2021. General and administrative expenses were $77.6 million for the nine-months ended September 30, 2022, an increase of $17.8 million compared to $59.8 million for the same period ended September 30, 2021. Thanks for taking our questions. Thanks for taking our questions. Thanks for taking our questions. Thanks for taking our questions."
}